Monthly Archives: September 2013

September 2 2013 – New pathway to treat colorectal cancer, pulmonary fibrosis

Israel researchers uncover secrets of how a certain white blood cell can flip from being a ‘good guy’ to a ‘bad guy’ in diseases with no current cure. Doctoral student Danielle Karo-Atar studying macrophages at Tel Aviv University. A type … Continue reading

Posted in Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, IPF, Long Fibrose, Lung Cancer, Lungen Fibrose, Medical, Pulmonary Fibrosis, Uncategorized | Tagged , , , , , , , , , , , , , , , , | Leave a comment

September 2 2013 – Boehringer Ingelheim to present highly anticipated data from landmark TIOSPIR™ trial, and their respiratory pipeline products in COPD, asthma, IPF and lung cancer at ERS 2013

INGELHEIM, Germany–(BUSINESS WIRE)– For media outside the UK, US and Canada Results of COPD Phase III landmark trial TIOSPIR™comparing safety and efficacy of SPIRIVA® Respimat® versus SPIRIVA® HandiHaler® Phase III trial results on investigational compound olodaterol* Respimat® as once-daily maintenance bronchodilator monotherapy in COPD … Continue reading

Posted in Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, IPF, Long Fibrose, Lung Cancer, Medical, Pulmonary Fibrosis, Uncategorized | Tagged , , , , , , , , , , , , , , , , , | Leave a comment

August 8 2013 – Aradigm Awarded NIH Grant to Investigate New Methods of Diagnoses of Aspirations of Gastrointestinal Contents into the Respiratory Tract with Scientists at UC San Francisco

HAYWARD, Calif.–(BUSINESS WIRE)– The National Heart, Lung, and Blood Institute, National Institutes of  Health (NIH), awarded Aradigm Corporation (ARDM) a Small Business  Initiative Research (SBIR) grant to investigate the development and  validation of tests for gastro-esophageal reflux with aspirations into  … Continue reading

Posted in Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, IPF, Long Fibrose, Lung Cancer, Medical, Pulmonary Fibrosis, Uncategorized | Tagged , , , , , , , , , , , , , , , , , | Leave a comment

August 5 2013 – Oral N-acetylcysteine (NAC) reduces COPD exacerbations in RCT (Chest)

Oxidative stress (imbalance between oxidants and antioxidants) is part of the story of how COPD causes symptoms of cough and shortness of breath. Cigarette smoke is the main source of oxidation damage in the lungs leading to COPD, but even … Continue reading

Posted in Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, IPF, Long Fibrose, Lung Cancer, Medical, Pulmonary Fibrosis, Uncategorized | Tagged , , , , , , , , , , , , , , , , , , | Leave a comment

August 3 2013 – Ambrisentan found ineffective against idiopathic pulmonary fibrosis

1. Ambrisentan is ineffective in delaying disease progression in idiopathic pulmonary fibrosis (IPF). 2. Compared to placebo, Ambrisentan is associated with increased risk of disease progression and respiratory hospitalization. Evidence rating level: 1 (Excellent) Study rundown: Idiopathic Pulmonary Fibrosis (IPF) is … Continue reading

Posted in Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, IPF, Long Fibrose, Lung Cancer, Medical, Pulmonary Fibrosis, Uncategorized | Tagged , , , , , , , , , , , , , , , , | Leave a comment

July 29 2013 – UVM hosts conference on revolutionary cell therapies to treat deadly lung diseases

On Monday, July 29, 2013, leading lung disease researchers from around the globe will participate in the fifth biennial “Stem Cells and Cell Therapies in Lung Biology Conference” at the University of Vermont (UVM). Since the meeting’s initiation eight years … Continue reading

Posted in Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, IPF, Long Fibrose, Medical, Pulmonary Fibrosis, Uncategorized | Tagged , , , , , , , , , , , , , , , , , , | Leave a comment

July 15 2013 – Compugen Announces US Patent Allowance for Drug Candidate Recently Presented at 2013 American Thoracic Society Meeting

Compugen Ltd. (NASDAQ: CGEN [FREE Stock Trend Analysis]) announced today that the  company has received an Issue Notification from the U.S. Patent and Trademark  Office for a patent application covering the company’s drug candidate  CGEN-25009. CGEN-25009 is intended for the … Continue reading

Posted in Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, IPF, Long Fibrose, Medical, Pulmonary Fibrosis, Uncategorized | Tagged , , , , , , , , , , , , , , , , , | Leave a comment

July 11 2013 – ProMetic’s Lead Drug Candidate, PBI-4050, on Track to Enter Clinical Trial Program in September 2013

LAVAL, QUEBEC–(Marketwired – July 11, 2013) – ProMetic Life Sciences Inc. (TSX:PLI) (OTCQX:PFSCF), (“ProMetic” or the “Corporation”) announced today that its lead drug candidate PBI-4050, is on track to enter the clinical trial program starting in September 2013. During the … Continue reading

Posted in Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, Medical, Pulmonary Fibrosis, Uncategorized | Tagged , , , , , , , , , , , , , , , , , , | Leave a comment

July 7 2013 – University of Washington’s first double lung transplant doing great 2 decades later

The first person to get a double lung transplant at the University of Washington is still breathing strong 20 years later. Ken Price had been living with cystic fibrosis since he was 1 year old, KOMO-TV reports. He was the … Continue reading

Posted in Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, IPF, Medical, Pulmonary Fibrosis, Uncategorized | Tagged , , , , , , , , , , , , , , , , , , | Leave a comment

July 2 2013 – New procedure to treat acid reflux can prevent chronic rejection in lung transplant patients

A Loyola University Medical Center study suggests that a procedure to treat acid reflux could help prevent chronic rejection in lung transplant patients. The study also found that certain proteins found in lung fluid can help predict whether a patient’s … Continue reading

Posted in Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, IPF, Medical, Pulmonary Fibrosis, Uncategorized | Tagged , , , , , , , , , , , , , , , , , | Leave a comment